Molecular Templates announces $9.5M private placement offering, amends second tranche of July 2023 deal

Molecular Templates, Inc.

Gross proceeds of $9.5M from amended second tranche; issuing 1.21M common shares, 2.46M prefunded warrants, and 7.34M common warrants at combined $2.60 per share and warrant.
Financing led by existing investor BVF Partners with BB Biotech AG and Santé.
Anticipated closing April 2, 2024; net proceeds to fund clinical studies, working capital, and general corporate purposes.
Stifel acting as sole placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Molecular Templates, Inc. amended Amended and Restated Securities Purchase Agreement with certain institutional and accredited investors (the "Purchasers") valued at $9.5 million (effective 2024-03-28).

Action: amendment
Agreement: equity purchase
Counterparty: certain institutional and accredited investors (the "Purchasers")
Value: $9.5 million
Effective: 2024-03-28

Exact text from the filing

On March 28, 2024, the Company and certain institutional and accredited investors (the “Purchasers”) entered into an Amended and Restated Securities Purchase Agreement (as amended and restated, the “Securities Purchase Agreement”) pursuant to which the Company will issue securities with an aggregate purchase price of $9.5 million on amended and restated second tranche terms.

View on SEC.gov

492 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-24-079769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.